Pulmonary Artery Sensor Program

Hartford Healthcare offers a remote monitoring program that allows patients with heart failure to send their pulmonary artery pressures directly to their team of clinicians, right from their home.

The pulmonary artery is the blood vessel that carries blood from the heart to the lungs. Pressure changes in the pulmonary artery may detect worsening heart failure.

Who is eligible for a Pulmonary Artery Sensor?

  • Patients with New York Heart Association (NYHA) class II or III heart failure
  • Patients with one heart failure hospitalization in the past 12 months and/or patient with an elevated BNP or NT-proBNP

Learn More

Patients & Caregivers

What is a pulmonary artery sensor?

  • The pulmonary artery sensor is a small, wireless device that is permanently placed in your pulmonary artery via a commonly performed right heart catheterization procedure.
  • The sensor allows patients to wirelessly transmit their pulmonary artery pressures through a secure website to their team of heart failure clinicians.
  • Pulmonary artery pressure monitoring provides early detection of worsening heart failure.
  • Early detection of worsening heart failure allows your team of clinicians to develop a proactive treatment plan before symptoms such as shortness of breath, weight gain, and swelling occur.

The CardioMEMS™ HF System

The CardioMEMS™ HF System enables earlier and more proactive heart failure treatment to slow down your heart failure progression and keep you out of the hospital.

Watch a video about how the CardioMEMS system works

CordelloMEMS PA Sensor

The Cordella™ Heart Failure System

The Cordella™ Heart Failure System by Endotronix, is an investigation device intended to electronically transfer communications and data from a set of medical devices in a heart failure patient’s home to a database for storage, retrieval, and display to healthcare providers.

Changes in PA pressure often indicate worsening heart failure 2-4 weeks before an urgent intervention is required. 1,2,3

Patient Outcomes

1. Abraham WT, et al. Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: a randomized control study. Lancet. 2011 Feb 19;377(9766):658-66.

2. Abraham WT, Adamson PB, et al. (2015, March). Pulmonary artery pressure management in heart failure patients with reduced ejection fraction significantly reduces heart failure hospitalizations and mortality above and beyond background guideline-directed medical therapy. Abstract 902-04 presented at ACC 2015, San Diego, CA.

3. Adamson, PB, Curr Heart Fail Reports 2009; 6:267.

Cordellla Heart Failure System

Learn more

To learn more about the Cordella™ Heart Failure System and the PROACTIVE-HF Clinical Trial, please visit: https://endotronix.com/heart-failure-management

Page content courtesy of Abbott and Endotronix

close

Healthcare Professionals

Hartford HealthCare's Heart & Vascular Institute offers two different wireless pulmonary artery pressure monitoring sensors.

The CardioMEMS™ HF System

The CardioMEMS™ HF System by Abbott is an FDA approved system that remotely monitors changes in pulmonary artery pressure.

The CardioMEMS™ HF System is indicated for patients with:

  • NYHA Class II or Class III heart failure and
  • One heart failure hospitalization in the past 12 months; and/or
  • Have elevated natriuretic peptides

Please refer to Abbott’s website for more information regarding the CardioMEMS™ HF System:

Click here

CardioMEMS™ HF System Press Releases:

Click here

The Cordella™ Heart Failure System

The Cordella™ Heart Failure System by Endotronix, is an investigational device intended to electronically transfer communications and data from a set of medical devices in a heart failure patient’s home to a database for storage, retrieval, and display to healthcare providers.

The PROACTIVE-HF Trial

The PROACTIVE-HF trial is deigned to evaluate a new medical device for management of heart failure called the Cordella™ Pulmonary Artery (PA) Pressure Sensor. The trial will assess the benefits of remote management using daily pulmonary artery pressure readings, a leading indicator of worsening heart failure symptoms.

For more information regarding the PROACTIVE-HF Trial, please visit clinicaltrials.gov (NCT04089059)

Select PROACTIVE-HF Criteria include:
  • Diagnosis of NYHA Class III heart failure
  • Hospitalization or IV diuretic therapy for heart failure in the last 12 months

The Cordella™ Heart Failure System is an investigational device and is not currently approved for clinical use in any geography. CAUTION – Investigational Device. Limited by Federal (or United States) Law to Investigational Use. Exclusively for Clinical Investigation.

For more information regarding the Cordella™ Heart Failure System,:

Click here

close